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Abstract: We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kid-
ney transplantation and continuous administration of immunosuppressive therapy. BcAC is a salivary gland malignancy first recognized 
as a distinct neoplastic entity in WHO classification of salivary gland tumours in 1991. Over 90% of BcACs are detected in the parotid 
gland. The most important differential diagnosis is basal cell adenoma. Infiltrative growth is the distinguishing feature of BcAC. Admin-
istration of immunosuppressive medication to this patient for three decades may have contributed to development of this rare neoplasia. 
To our knowledge, similar cases of BcAC have not been reported previously.
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Introduction
Histopathology of BcAC is characterized by two cell 
types: small basaloid epithelial cells at the periphery 
of tumour clusters and larger epithelial cells situated 
centrally in tumour clusters. Different histological 
growth patterns are seen, i.e. solid, trabecular, tubular 
and membranous types. In general, BcAC possesses 
a good prognosis. It metastasizes seldom, but may 
recur locally.1,2 Although BcAC may develop from a 
primary basal cell adenoma, it often grows de novo. 
The differential diagnosis includes other neoplasms 
containing basal cells. Chondromyxoid stroma seen 
in pleomorphic adenoma is absent from basal cell 
adenomas and BcACs.2,3 Differential diagnosis with 
high grade malignancies, e.g. adenocystic carcinoma 
(ACC), is important because of the low malignant 
behaviour and good prognosis of BcAC. However, 
the main differential diagnosis of BcAC is a benign 
basal cell adenoma. The two may share virtually sim-
ilar histologic appearances. Criteria for the diagnosis 
of  BcAC  include  infiltrative  growth  with  possible 
perineural or vascular invasion. Other features may 
include nuclear pleomorphism, necrosis and mitotic 
activity.  The  differential  diagnosis  of  ACC  must 
also  be  considered.  BcAC  lacks  the  architectural 
pattern  of  pseudocysts  and  true  glands  within  the 
same tumour islets that is typical for ACC.2,4,5 Immu-
nohistochemistry with basal cell markers, e.g. p63 
and CK14, may be helpful in differential diagnosis 
of BcAC suggesting basal cell derivation of tumour 
cells. Cell proliferation markers, such as Ki67, are 
often suggestive in the differentiation of BcAC from 
basal  cell  adenomas  and  pleomorphic  adenomas. 
However, invasive growth remains the only decisive 
criteria of malignancy.1,2
Renal transplantation is known to raise the life-long 
incidence of malignancies.6 A recent Finnish study 
showed a 0.8% overall incidence for non-cutaneous 
head and neck cancer during 10 years of follow-up 
after renal transplantation.7 We describe a rare case 
of bilateral BcAC arising in the parotid glands of a 
kidney recipient 30 years after transplantation.
case Report
A  male  patient  aged  60  years  had  a  history  of 
chronic  glomerulonephritis,  which  finally  evolved 
into terminal uremia. Renal transplantation from a 
cadaver source was successfully performed in 1977. 
The  anti-rejection  drug  regimen  for  the  first  post 
transplantation decade was azathioprine and methyl-
prednisolone, then azathioprine combined with cyclo-
sporine for 15 years and finally from 2005 onwards 
only cyclosporine as monotherapy.
In 2003, he was operated for a malignant mela-
noma of the skin of chest (Clark IV, Breslow 2,3 mm 
with clean sentinel nodes). No signs of recurrence 
were seen during follow-up.
He presented in 2007 for a midline neck pain in the 
thyroid region after having a common cold 2 months 
previously. Ultrasonography revealed an asymptom-
atic lesion of 10 mm in the right and 6 mm in the left 
parotid gland (Figs. 1 and 2). Fine needle aspiration 
of the right side showed a slight suspicion of malig-
nancy, while the lesion of the left parotid was inter-
preted as a basal cell adenoma.
A right partial parotidectomy was performed and 
a  preoperative  frozen  section  was  interpreted  as  a 
pleomorphic  adenoma.  However,  in  paraffin  sec-
tions of the resected tissue invasive tumour growth 
into connective tissues surrounding parotid gland was 
seen confirming BcAC as the final diagnosis. Con-
sequently, a total parotidectomy was performed one 
week later. The superficial lobe of the left parotid 
gland was operated two months later. In histological 
examination of the left superior lobe, three foci of 
BcAC were also seen displaying invasive growth into 
surrounding tissues.
Neck  ultrasonography  and  plain  chest  x-ray 
indicated  no  signs  of  metastasis  to  locoregional 
lymph  nodes  or  distant  sites.  In  histologic  exami-
nation,  both  tumours  showed  appearance  of  basal 
cell adenocarcinomas with a mainly tubular growth 
pattern (Figs. 3A, E). The tumours in both parotid 
glands occurred multifocally, and were only partly 
encapsulated. Distinct invasive growth into adipose 
tissue was detected (Fig. 3B). Cellular and nuclear 
pleomorphism was only slight. Immunohistochemis-
try for Ki-67 antigen (Mib-1 antibody) showed cell 
proliferation of 5% in the left ( Fig. 3H), and 10% in 
the right side (Fig. 3D), respectively.
Discussion
The basaloid parotid tumours in our case showed fea-
tures of invasive growth that are a hallmark of basal 
cell adenocarcinomas. In our patient the differential 
diagnoses of basal cell adenocarcinoma, basal cell BcAC of the parotid gland
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Figure . Ultrasonography imaging of the right parotid gland tumour.
Figure . Ultrasonography imaging of the left parotid gland tumour.Markkanen-Leppänen et al
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Figure . Bilateral Basel cell adenocarcinoma in parotid: Tubular tumour growth seen (A) in right side and (e) in left side parotid cell adenocarcinoma. 
(B, c) Infiltrative growth and (G) lymph node infiltration within parotid tissue marked with arrows. (D, H) Increased proliferation detected by Mib-1(Ki-67) 
immunohisto chemistry. Normal parotid tissue (F). Magnification ×400, except B ×100.
adenoma and pleomorphic adenoma were taken into 
consideration.  The  differential  diagnosis  of  BcAC 
and basal cell adenoma can be difficult as the level of 
cytological atypia in many cases of BcAC is not sig-
nificantly different from that seen in basal cell adeno-
mas. However, in such cases invasive growth is the 
main distinguishing feature. In FNAC, BcAC often 
cannot be distinguished from basal cell adenoma and 
pleomorphic adenoma, especially if there is lack of 
cellular atypia.8,9
The proliferation index (Mib-1, Ki-67) being over 
5% is a statistical marker predicting malignancy10 and 
in our case it was over 5% in both parotid tumours. 
Development  of  skin  cancer  2  to  3  decades  after 
organ transplantation and immunosuppressive ther-
apy is not unusual.7,11,12 The majority of such cutane-
ous malignancies appear in the head and neck region. 
However,  transplantation  and  immunosuppressive 
therapy raise the risk of non-cutaneous head and neck 
malignancies  four-fold.7  Our  patient  had  presented 
with a malignant melanoma of the skin 26 years after 
kidney  transplantation. The  medical  history  of  the 
patient does not include irradiation which is the only 
known risk factor for salivary gland malignancies.2 
Interestingly BcAC has been reported in connection 
with cylindroma and other adnexal tumours.13 Cases 
of bilateral basal cell adenoma have been reported 
before but to our knowledge cases of bilateral BcAC 
have not been reported.14
conclusion
Immunosuppressive therapy after kidney transplan-
tation clearly increases the incidence of neoplastic 
conditions.  We  suggest  a  connection  between  the 
bilaterality and multifocality of the present parotid 
BcAC, and immunosuppression following the renal 
transplantation.  Minimizing  or  even  interrupting 
this  medication  should  be  carefully  considered  in 
such patients if cancer is diagnosed. The nefrologists 
in charge of the present patient are working on the 
options to minimize the immunosuppressive medica-
tions of the patient. No concensus prevails concern-
ing the guidelines of what kind of changes ought to be 
made to the anti-rejection treatment after a transplan-
tation patient having been developed a cancer.
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